These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 18021486)

  • 41. Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.
    Chua YJ; Cunningham D
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S81-8. PubMed ID: 16336753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
    Köhne CH; Lenz HJ
    Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
    Snyder LC; Astsaturov I; Weiner LM
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Biotherapy in colorectal cancer].
    Des Guetz G
    J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
    J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal antibodies in the treatment of advanced colorectal cancer.
    Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
    Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.
    Mancl EE; Kolesar JM; Vermeulen LC
    Am J Health Syst Pharm; 2009 Dec; 66(23):2105-12. PubMed ID: 19923311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of panitumumab in the management of metastatic colorectal cancer.
    Saif MW; Cohenuram M
    Clin Colorectal Cancer; 2006 Jul; 6(2):118-24. PubMed ID: 16945167
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice.
    Hecht JR
    Am J Health Syst Pharm; 2008 Jun; 65(11 Suppl 4):S15-21; quiz S22-4. PubMed ID: 18499885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-EGFR therapy in colorectal cancer: how to choose the right patient.
    Meriggi F; Di Biasi B; Abeni C; Zaniboni A
    Curr Drug Targets; 2009 Oct; 10(10):1033-40. PubMed ID: 19663767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
    Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
    Xu W; Jing H; Zhang F
    Front Biosci (Landmark Ed); 2016 Jan; 21(2):410-8. PubMed ID: 26709782
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of targeted therapy in the treatment of advanced colorectal cancer.
    Fakih M
    Curr Treat Options Oncol; 2008 Dec; 9(4-6):357-74. PubMed ID: 19238551
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cetuximab: from bench to bedside.
    Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
    Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
    Saif MW; Kaley K; Chu E; Copur MS
    Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.